Paper Details

  1. Home
  2. Paper Details

Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection.

Author: BenedettiJ, ConnorJ, CritchlowC W, DolinR, MertzG J, RedfieldD C, ReichmanR C, RichmanD D, SavoiaM C, TyrrellD L

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A study of 150 patients with first-episode genital herpes found that oral acyclovir significantly shortened the duration of viral shedding, symptoms, and healing for patients with primary genital herpes. It did not affect subsequent recurrences.
Paper Details　
Original Abstract of the Article :
One hundred nineteen patients with primary and 31 patients with nonprimary first-episode genital herpes were treated for ten days with 200 mg of acyclovir capsules or placebo capsules orally five times daily. Among acyclovir recipients with primary genital herpes, the median duration of viral sheddi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/6088819

データ提供：米国国立医学図書館（NLM）

Acyclovir: A Promising Treatment for Genital Herpes

Dr. Camel's research journey has often led him to the study of viral infections, and this study explores the effectiveness of oral acyclovir in treating first-episode genital herpes simplex virus infection. Researchers compared the outcomes of patients treated with oral acyclovir to those who received a placebo. This study aimed to evaluate the efficacy of oral acyclovir in reducing the duration of viral shedding, symptoms, and healing time in patients with first-episode genital herpes.

The Benefits of Acyclovir for Genital Herpes

The study found that oral acyclovir significantly reduced the duration of viral shedding, symptoms, and accelerated healing in patients with primary first-episode genital herpes. However, it did not have a significant impact on subsequent recurrences. This research highlights the potential of acyclovir as a treatment option for reducing the severity and duration of initial herpes outbreaks.

Managing Genital Herpes

Dr. Camel advises individuals experiencing symptoms of genital herpes to consult with a healthcare professional for prompt diagnosis and treatment. A healthcare provider can recommend appropriate medications, such as acyclovir, to reduce the severity and duration of outbreaks and to minimize the risk of transmission. This study underscores the importance of seeking medical advice for managing viral infections and adhering to prescribed treatment plans.

Dr. Camel's Conclusion

Dr. Camel is encouraged by the findings of this study, highlighting the potential of acyclovir to alleviate the symptoms of genital herpes. This research underscores the importance of early diagnosis and effective treatment for viral infections. Dr. Camel emphasizes the need for ongoing research to develop new and more effective antiviral medications to combat the challenges of viral diseases.

Date :
  1. Date Completed 1984-10-16
  2. Date Revised 2016-10-17
Further Info :

Pubmed ID

6088819

DOI: Digital Object Identifier

6088819

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.